Innoviva INVA 深 滬
已收盤 08-07 16:00:00 美东时间
20.51
-0.600
-2.84%
華盛通- 最 高20.96
- 今 開20.93
- 成交量 114.33万股
- 最 低 20.20
- 昨 收 21.11
- 總市值 15.14亿
- 52周最高 25.145
- 市盈率 靜 6.21
- 換手率 1.55%
- 52周最低 16.52
- 委 比 -39.82%
- 總股本 7380.87万
- 歷史最高 41.96
- 量 比 1.47
- 振 幅 3.60%
- 歷史最低 6.36
- 每 手 1
- 風險率 1.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cantor Fitzgerald Maintains Overweight on Innoviva, Lowers Price Target to $34
Cantor Fitzgerald analyst Steve Seedhouse maintains Innoviva (NASDAQ:INVA) with a Overweight and lowers the price target from $36 to $34.
08-07 20:36
Innoviva Q2 EPS $(1.14) Misses $0.40 Estimate, Sales $119.600M Beat $110.985M Estimate
Innoviva (NASDAQ:INVA) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $0.40 by 385 percent. This is a 248.05 percent decrease over earnings of $0.77 per share from the same period last year. The company reported quarterly sales of $119.600 million which...
08-06 04:43
Top profitable small caps trading at bargain P/E multiples during Q2 earnings
As the market moves through second-quarter earnings season, investors are paying close attention to small-cap stocks that combine solid profitability with attractive valuations. Price-to-earnings rat...
07-27 21:09
美股夜盘 | Vista Oil & Gas涨4.88%，Venture Global涨4.58%
Vista Oil & Gas涨4.88%；Venture Global涨4.58%；塞拉尼斯涨3.52%
07-13 13:01
美股大行评级 | 瑞杰金融上调美光目标价从530美元升至1100美元；AMD、Arm、戴尔、英特尔等获多家机构上调目标价
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从13.5美元升至14美元；BTIG：维持Jade Biosciences"买入"评级，目标价从39美元升至74美元
06-02 16:25
美股大行评级 | 市值直指1.8万亿美元？瑞银给出美光1600美元天价目标！华尔街绩前集体上调迈威尔科技目标价
今日重点评级关注：Canaccord Genuity：维持Dakota Gold"投机性买入"评级，目标价从16美元升至18美元；瑞杰金融：上调Tectonic Therapeutic评级至"强烈买入"，目标价从76美元升至81美元
05-27 17:33
BTIG Reiterates Buy on Innoviva, Maintains $42 Price Target
BTIG analyst Julian Harrison reiterates Innoviva (NASDAQ:INVA) with a Buy and maintains $42 price target.
05-26 19:08
美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
BTIG Maintains Buy on Innoviva, Raises Price Target to $42
BTIG analyst Julian Harrison maintains Innoviva (NASDAQ:INVA) with a Buy and raises the price target from $35 to $42.
05-07 18:17
